TEANECK, N.J., July 24, 2017 -- The Board of Directors of Phibro Animal Health Corporation (Nasdaq:PAHC) today declared a quarterly cash dividend of $0.10 per share on its Class A common stock and Class B common stock, payable on September 27, 2017, to stockholders of record at the close of business on September 6, 2017.
About Phibro Animal Health Corporation
Phibro Animal Health Corporation is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for use in the production of poultry, swine, cattle, dairy and aquaculture. For further information, please visit www.pahc.com.
Contact: Richard Johnson Chief Financial Officer, Phibro Animal Health Corporation +1 201-329-7300 [email protected]


Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 



